[go: up one dir, main page]

MX2020010075A - Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. - Google Patents

Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.

Info

Publication number
MX2020010075A
MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A
Authority
MX
Mexico
Prior art keywords
lysin
constructs
lysines
encode
isolated
Prior art date
Application number
MX2020010075A
Other languages
English (en)
Inventor
Raymond Schuch
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2020010075A publication Critical patent/MX2020010075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente descripción se dirige a construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas que comprenden los polipéptidos aislados y/o construcciones de lisina-polipéptidos AMP. También se proporcionan en este documento métodos para usar las construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas, incluidos métodos para tratar una infección bacteriana de un órgano o tejido en el que está presente un tensioactivo pulmonar o infecciones bacterianas Gramnegativas que están asociadas con una biopelícula. Además, los polinucleótidos aislados que codifican para las construcciones de lisina polipéptido AMP y los polipéptidos de lisina aislados se describen en este documento.
MX2020010075A 2018-03-29 2019-03-29 Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. MX2020010075A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862650235P 2018-03-29 2018-03-29
US201862721969P 2018-08-23 2018-08-23
US201862722793P 2018-08-24 2018-08-24
PCT/US2019/024912 WO2019191633A2 (en) 2018-03-29 2019-03-29 Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010075A true MX2020010075A (es) 2021-01-08

Family

ID=68060804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010075A MX2020010075A (es) 2018-03-29 2019-03-29 Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.

Country Status (11)

Country Link
US (2) US11773140B2 (es)
EP (1) EP3775192A4 (es)
JP (1) JP2021519083A (es)
KR (1) KR20200136980A (es)
CN (1) CN112368376A (es)
AU (1) AU2019245369A1 (es)
BR (1) BR112020019484A2 (es)
CA (1) CA3095484A1 (es)
IL (1) IL277119B2 (es)
MX (1) MX2020010075A (es)
WO (1) WO2019191633A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725809C2 (ru) * 2014-06-26 2020-07-06 Дзе Рокфеллер Юниверсити Лизины ацинетобактеров
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
EP3773669A4 (en) * 2018-03-29 2022-04-27 Contrafect Corporation ANTIMICROBIAL BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
AU2019327378A1 (en) * 2018-08-23 2020-10-29 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2020206327A1 (en) * 2019-04-05 2020-10-08 Contrafect Corporation Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
BR112021025948A2 (pt) * 2019-07-05 2022-02-08 Contrafect Corp Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes
EP4058468A4 (en) * 2019-11-14 2024-04-10 Contrafect Corporation POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
JP2024513181A (ja) * 2021-03-26 2024-03-22 コントラフェクト コーポレイション グラム陰性細菌に対して活性なアムリン、溶解素、及び溶解素－抗微生物ペプチド（ａｍｐ）コンストラクト
WO2022236088A1 (en) * 2021-05-06 2022-11-10 Bioharmony Therapeutics Inc. Lysin polypeptide compositions and methods of use
CN121358455A (zh) * 2023-06-02 2026-01-16 莱雅公司 包含衍生自金黄色葡萄球菌噬菌体的内溶素和芳族醇的化妆品组合物
FR3149202A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149203A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3149209A1 (fr) * 2023-06-02 2024-12-06 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024256710A2 (en) 2023-06-15 2024-12-19 Aurobac Therapeutics Sas Engineered lysin polypeptide constructs active against gram-negative bacteria
WO2025054593A2 (en) * 2023-09-07 2025-03-13 The Trustees Of The University Of Pennsylvania Molecular de-extinction of antibiotics enabled by deep learning
CN120924524B (zh) * 2025-10-14 2026-01-06 中国海洋大学 一种抗菌肽及其制备方法和在制备治疗肺炎的制剂中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007003991A0 (en) 2004-11-12 2007-06-30 Novozymes As Polypeptides having antimicrobial activity and polynucleotides encoding same
US20120135917A1 (en) 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
KR101711062B1 (ko) 2009-06-26 2017-02-28 카톨리에케 유니버시테이트 루벤 항균제
EP2446028B1 (en) * 2009-06-26 2018-04-04 Lysando Aktiengesellschaft Antimicrobial agents
CN102575240B (zh) 2009-08-24 2016-01-13 勒芬天主教大学，K.U.勒芬R&D 新的细胞内溶素OBPgpLYS
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
US20140179594A1 (en) 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US9518252B2 (en) 2011-05-26 2016-12-13 Dsm Ip Assets B.V. Listeria bacteriophage P825 and uses thereof
US8790639B2 (en) 2012-03-28 2014-07-29 The United States Of America, As Represented By The Secretary Of Agriculture Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin
KR101391332B1 (ko) 2012-05-18 2014-05-07 연세대학교 산학협력단 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지
US9388400B2 (en) * 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
CN102861324A (zh) 2012-10-17 2013-01-09 重庆市第三人民医院 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂
RU2725809C2 (ru) 2014-06-26 2020-07-06 Дзе Рокфеллер Юниверсити Лизины ацинетобактеров
JP7029805B2 (ja) * 2015-09-17 2022-03-04 コントラフェクト コーポレイション グラム陰性菌に対して活性を有する溶解素ポリペプチド
KR102000120B1 (ko) 2017-01-26 2019-07-15 주식회사 코미팜 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물
BR112020011433A2 (pt) 2017-12-12 2020-12-01 Contrafect Corporation identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa
US10988520B2 (en) 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3773669A4 (en) 2018-03-29 2022-04-27 Contrafect Corporation ANTIMICROBIAL BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA
WO2019191633A2 (en) 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
AU2019327378A1 (en) * 2018-08-23 2020-10-29 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis

Also Published As

Publication number Publication date
US20210047374A1 (en) 2021-02-18
JP2021519083A (ja) 2021-08-10
CA3095484A1 (en) 2019-10-03
IL277119B1 (en) 2025-04-01
IL277119A (en) 2020-10-29
KR20200136980A (ko) 2020-12-08
WO2019191633A2 (en) 2019-10-03
US11773140B2 (en) 2023-10-03
CN112368376A (zh) 2021-02-12
IL277119B2 (en) 2025-08-01
EP3775192A2 (en) 2021-02-17
US20240018192A1 (en) 2024-01-18
BR112020019484A2 (pt) 2021-01-12
AU2019245369A1 (en) 2020-10-29
WO2019191633A3 (en) 2019-11-07
RU2020129467A (ru) 2022-05-04
EP3775192A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
AR114445A1 (es) Conjugados de il-15, y sus usos
CR20230026A (es) Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532)
MX2018005063A (es) Polipéptidos condicionalmente activos.
UY37456A (es) Inmunoglobulinas y sus usos
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
MX388739B (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
MX2019011599A (es) Moleculas quimericas y usos de las mismas.
PE20240817A1 (es) Mutantes de proteina f de rsv
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX2021001129A (es) Metodo de purificacion de antigenos.
EA201990822A1 (ru) Иммуномодулирующие слитые белки
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112016025450A2 (pt) moduladores de canais de íons e usos dos mesmos
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
BR112021013206A2 (pt) Bibliotecas de peptídeos e respectivos métodos de uso
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.